Kornimate/medical-research-clean huggingface dataset:
does positive pressure extubation reduce postoperative desaturation?

Conditions: Extubation; Postoperative Complications; Lung Ultrasound Score

Summary: single-center, prospective, controlled, parallel, randomized, single-blind study comparing the conventional extubation technique to two positive pressure extubation techniques on postoperative desaturations

study realise on university hospital on lille in france. patients inclusion is prospective and randomised in three groups. first group : extubation is realised with aspiration in tracheal tube during removal tube second group : extubation is realised without aspiration but with apl valve set to 20cmh20 third group : extubation is realised without aspiration but with ventilator parameters were set for psv mode (inspiratory pressure of 10cmh2o and peep identical to that administered in the operating room

Eligibility criteria:
inclusion criteria: * visceral or urological surgery * scheduled surgery * surgical or patient requirement: placement of an arterial catheter * supine position * post-surgical extubation scheduled in the operating room * minimum age of 18 years * informed and signed consent exclusion criteria: * severe obesity (bmi over 35kg/m2) * pregnant woman * acute or chronic preoperative respiratory pathology. * sleep apnea syndrome * inability to receive informed information (does not speak, read or understand french) * patient under guardianship or curatorship * lack of social security coverage * history of intubation or criteria for difficult intubation or ventilation.

Keywords: positive pressure extubation postoperative complications lung ultrasound score
personalized fiber and insulin sensitivity

Conditions: Type 2 Diabetes; Insulin Resistance

Summary: in this project the investigators intend to study the therapeutic potential of a personalized fibre mixture in individuals at high risk of developing t2dm, and aim to address the following key objectives: 1. to investigate whether a mixture of fermentable fibres, which differ in dp and side chains, will stimulate a broad range of scfa-producing bacterial genera, resulting in enhanced chronic scfa production throughout the whole colon with a large variation between individuals; 2. to unravel whether providing personalized fibre mixtures, selected based on the individuals' initial microbiota and capacity for scfa production is crucial to successfully improve host insulin sensitivity and metabolic health


Eligibility criteria:
inclusion criteria: overweight/obese insulin resistant/prediabetic participants (age 30-70 y, bmi ≥ 28 kg/m2 \< 40 kg/m2) exclusion criteria: * type 2 diabetes mellitus (defined as fasting plasma glucose ≥ 7.0 mmol/l and 2h glucose ≥ 11.1 mmol/l) * gastroenterological diseases or abdominal surgery; * cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter than 5 years; * abuse of products; alcohol and drugs, excessive nicotine use defined as \>20 cigarettes per day; * plans to lose weight or following of a hypocaloric diet; * regular supplementation of pre- or probiotic products, use of pre- or probiotics 3 months prior to the start of the study; * intensive exercise training more than three hours a week; * use of any medication that influences glucose or fat metabolism and inflammation (i.e. nsaids); * regular use of laxation products; * use of antibiotics in the last three months (antibiotics use can alter substantially the gut microbiota composition). * follow a vegetarian diet.
study to evaluate the value of the follow-up of calcineurin activity to modulate calcineurin inhibitors-induced immunosuppression in lung transplantation

Conditions: Lung Diseases

Summary: the study is an interventional, multicentre, prospective, randomized, controlled, single-blind, comparative trial of two processes for adjusting the inhibitor of calcineurin (cni) dosage in lung transplant recipients. recipients will be stratified by transplant center and according to the underlying lung disease (affected with cystic fibrosis or not) and will be randomized to either evaluation of calcineurin activity (cn-a) in combination with cni blood levels versus cni blood levels alone in a 1:1 ratio. the objective is to compare the proportion of acute rejection that has required a specific curative treatment at 6 months after transplantation between patients in the two groups.


Eligibility criteria:
inclusion criteria: * patient placed on the national waiting list for lung transplantation * first de novo lung transplantation (single or double ltx) * prevention of allograft rejection by a usual immunosuppressive regimen including cni (cyclosporine or tacrolimus) exclusion criteria: * previous lung transplantation or other solid organ transplantation * combined lung transplantation with either liver or renal transplantation

Keywords: lung transplantation in end-stage lung diseases
exercise for fibromyalgia

Conditions: Fibromyalgia

Summary: randomized equivalency trial of the effects of strength training compared to aerobic exercise on pain severity in adults with fibromyalgia.


Eligibility criteria:
inclusion criteria: - established diagnosis of fibromyalgia, age \> 18 years. exclusion criteria: cardiac, pulmonary or orthopedic condition that would limit exercise. -

Keywords: exercise pain
cardiac rehabilitation in patients with continuous flow left ventricular assist devices:rehab vad trial

Conditions: Heart Failure

Summary: cardiac rehabilitation programs improve mortality, functional capacity, and quality of life, for a variety of patients with heart disease. it stands to reason that patients with lvads might therefore also benefit from the same structured exercise training, education, and clinical surveillance. one potential benefit of cardiac rehabilitation in this patient population is reversal of the skeletal muscle atrophy that occurs due to extended periods of poor peripheral perfusion (i.e. before implantation) and prolonged sedentary behavior. purpose: the purpose of this proposed study is to examine the effects of a 6-week exercise program on cardiorespiratory fitness, quality of life, and device flow rate in patients with recently implanted lvads. methods: 30 patients with recently implanted lvads will be referred by the henry ford hospital advanced heart failure program once the patient is deemed appropriate for exercise. before enrollment into cardiac rehabilitation patients will undergo a six minute walk test and graded exercise stress test on a treadmill to determine exercise capacity. additionally, a quality of life questionnaire will be given. following the stress test, patients will be randomized (2 to 1 ratio) into either cardiac rehabilitation or control. those chosen to be in the control group will be encouraged to maintain daily activities; those in the rehabilitation group will partake in 6 weeks of a standard cardiac rehabilitation program. this will consist of 3 days a week of supervised exercise as well as education regarding diet and lifestyle modifications. at 6 weeks after randomization both groups will again undergo fitness assessments and retake the quality of life questionnaires.


Eligibility criteria:
inclusion criteria: * continuous flow left ventricular assist device * implanted within the past six months * approval from cardiologist to participate in cardiac rehabilitation * age greater or equal to 18 years * no history of cardiac rehabilitation participation since receiving a lvad exclusion criteria: * orthopedic limitations to perform exercise * current infection related to lvad * severe anemia * recent cva related to lvad implant that affects ability to exercise * unable to attend cardiac rehabilitation at henry ford hospital * uncontrolled metabolic disorders
effectiveness of a physiotherapy treatment for temporomandibular hyperlaxity

Conditions: Disorders, Temporomandibular Joint; Range of Motion, Articular

Summary: a 14-day physiotherapy treatment for temporomandibular joint hyperlaxity is established. pre-intervention measurements and intermediate and end-of-treatment measurements are taken. range of movement, algometry and muscle balance are assessed.


Eligibility criteria:
inclusion criteria: * woman with temporomandicular joint pain for six months and diagnosed with hyperlaxity in the joint. exclusion criteria: * men * no temporomandibular joint pain or hyperlaxity

Keywords: range of motion, articular disorders, temporomandibular joint
a mechanistic study of inhaled nitric oxide in copd

Conditions: Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension

Summary: there is a lack of effective treatments for chronic obstructive pulmonary disease (copd) complicated with pulmonary hypertension. previous studies have found that inhaled nitric oxide (ino) can reduce pulmonary artery pressure and improve exercise capacity in copd with pulmonary hypertension patients. however, the specific mechanism is unclear. the study aims to evaluate pulmonary ventilation/perfusion, pulmonary artery pressure, oxygenation, symptoms and quality of life in copd with pulmonary hypertension patients after short-term treatment with ino. observing a series of pathophysiological changes caused by the treatment of pulmonary hypertension with ino in copd, the investigators hope to provide new theoretical basis and research ideas.


Eligibility criteria:
inclusion criteria: 1. age ≥ 40 years, ≤ 75 years 2. currently smoking or former smokers with at least 10 pack-years of tobacco cigarette smoking history 3. diagnosis of moderate and severe copd by the global initiative for chronic obstructive lung disease (gold) 2022 criteria: a post-bronchodilatory forced expiratory volume in 1 second/forced vital capacity (fev1/fvc) \< 0.7, and 30%\< fev1 \< 80% predicted 4. echocardiogram with technical adequacy demonstrating with pulmonary hypertension: tricuspid regurgitation velocity (trv) \> 2.8 m/s or pulmonary arterial systolic pressure (spap) ≥38mmhg 5. signed informed consent prior to the initiation of any study mandated procedures or assessments exclusion criteria: 1. experienced an exacerbation requiring start of or increase in systemic oral corticosteroid therapy during the last month 2. treatment with antibiotics 3. respiratory failure requiring supplemental oxygen therapy 4. a diagnosis of interstitial lung disease, asthma, tuberculosis, bronchiectasis, pneumonia, lung cancer, pulmonary embolism, or other non-copd respiratory disease 5. any history of lung resection 6. left ventricular dysfunction: left ventricular ejection fraction (lvef) \< 40% 7. clinically significant valvular heart disease, including aortic valvular disease (moderate or greater aortic stenosis or regurgitation) and/or mitral valve disease (moderate or greater mitral stenosis or regurgitation), or status post mitral valve replacement 8. use within 30 days of screening or current use of approved ph medications such as sildenafil, bosentan or prostacyclines 9. neuromuscular disease or musculoskeletal injuries that unable to complete exercise trials 10. use of investigational drugs or devices within 30 days prior to enrollment into the study 11. any underlying medical or psychiatric condition that, in the opinion of the investigator, makes the subject an unsuitable candidate for the study
orexin-a levels in insomnia patients

Conditions: Insomnia; Anesthesia

Summary: in the pathophysiology of insomnia, the increase of the orexin-a (oxa) peptide released from orexin neurons in the lateral hypothalamus plays an important role. orexins takes part at the emergence of anesthesia. in the literature, investigators could not attain any studies about the arousal of insomnia patients from anesthesia. in this study, the effect of this peptide on the emergence process from anesthesia was investigated by comparing plasma oxa levels before and after anesthesia in insomnia patients.

asa (american society of anesthesiologists) i-ii patients aged 18-65 years who underwent elective laparoscopic cholecystectomy were included in the study. patients were evaluated with the jenkins sleep disorders scale and epworth sleepiness scale during preoperative examination and were divided into insomnia and control groups. blood samples were obtained for oxa and glucose levels at anesthesia induction, 5 minutes after extubation and 30 minutes after extubation. the times from stopping anesthesia to eyes opening and extubation and end-tidal sevoflurane concentrations at these time points were recorded.

Eligibility criteria:
inclusion criteria: * male patients undergo elective laparoscopic cholecystectomy under general anesthesia * between 18-65 age * asa i-ii exclusion criteria: * asa≥iii * patients with obstructive sleep apnea syndrome * bleeding over 500 ml * allergic to anesthetic agents * patients with a bmi \> 30 kg/m2
acute viral respiratory infections in elderly

Conditions: Respiratory Infections, Acute

Summary: this study is designed to assess the causes and impact of acute respiratory illness (common colds, flu, bronchitis, pneumonia) in adults age 65 and older. one of the ways to determine the virus causing a particular illness is to get a blood specimen when a person is sick and again later and look for the body's specific responses that identify the virus. approximately 3000 subjects will be evaluated and their medical records assessed for details of recent illness and general health to help in understanding the subjects' current illness.

the purpose of this study is to determine the role of respiratory viruses in the etiology of medically attended acute respiratory illness in elderly populations and to assess the impact of these illnesses. ambulatory elders presenting for health care with an acute respiratory illness will be recruited. nose and throat swab specimens will be collected to test for one of the respiratory viruses, and acute and convalescent blood specimens will be collected to test for increases in specific antibody. specimens will be collected within seven days of the onset of illness and then 1 month later for comparison specimens. a brief questionnaire will accompany the specimens, and more complete data on the illness and consequences will be obtained from the medical record. the pattern of illnesses by virus and their severity and duration will be determined.

Eligibility criteria:
inclusion criteria: 1. 65 years of age or older 2. presentation to the geriatric clinic with an acute respiratory illness of less than 7 days' duration. exclusion criteria: 1. presentation to the geriatric clinic with a history of a respiratory illness of greater than 7 days' duration. 2. physician/physician assistant judgment that the respiratory complaints do not represent an acute infection. 3. patient declines to permit specimen collection.

Keywords: respiratory illness, influenza, bronchitis, pneumonia, cold
study of e3810 for healthy japanese male (under fasting condition)

Conditions: Healthy

Summary: the purpose of this study is to assess the pharmacokinetics of rabeprazole under fasting condition.

the purpose of this study is to assess bioequivalence after single administration of the following 4 types of formulation: normal 10 mg rabeprazole tablet rabeprazole, and type 1, type 2, and type 3 granule formulation containing rabeprazole 10 mg.

Eligibility criteria:
inclusion criteria: subjects with homozygous or heterozygous extensive metabolizers of cytochrome p4502c19. exclusion criteria: subjects with allergy

Keywords: rabeprazole japan healthy japanese male
evaluating the feasibility of a dietary weight loss program to overcome obesity and its comorbidity among arab populations

Conditions: Overweight and Obesity

Summary: this study aims to develop and test a culturally tailored online weight loss program for the saudi population. building upon the success of a previous program in the united states, the research team will adapt educational materials and conduct a pilot study to assess the feasibility and initial outcomes of the program among arab participants. the study seeks to answer questions about the program's acceptability, effectiveness, and scalability, with the ultimate goal of combating obesity and its related health issues in saudi arabia.

this research project aims to help saudi individuals lose weight in a way that suits their culture. obesity is a significant problem and can lead to serious health issues like diabetes and heart problems. even though saudi arabia has attempted to help individuals lose weight before, previous efforts haven't been successful enough. therefore, the investigators aim to develop a new weight loss program that is better suited to saudi individuals. first, educational materials will be created in arabic to teach individuals how to eat better and live healthier. then, collaboration will be undertaken with individuals in saudi arabia to ensure the program fits their needs. afterward, the program will be tested with a small group of individuals to evaluate its effectiveness and acceptability. approximately 20 individuals will be invited to join the program at king abdullah medical city. they will participate in ten online sessions, where they will learn about healthy eating and lifestyle improvements. additionally, they will regularly weigh themselves. data will be collected before and after the program to assess its impact on weight loss and overall well-being. by the end of the project, the investigators hope to have developed an effective program that assists saudi individuals in losing weight and maintaining good health.

Eligibility criteria:
inclusion criteria: * adults within the age range of 18 to 75 years old * individuals with a bmi greater than 25 kg/m² * proficient in the arabic language * not currently pregnant or breastfeeding * not using glucagon-like peptide -1 (glp-1) or any weight loss medications * have not undergone bariatric surgery * possess wi-fi connectivity at their residence * own a smartphone * willing to provide consent for participation in 10 educational sessions spanning three months. exclusion criteria: * individuals not meeting the inclusion criteria.

Keywords: online weight loss program feasibility assessment dietary education sustainable weight loss pilot study
study comparing a 13-valent pneumococcal conjugate vaccine with 23-valent pneumococcal polysaccharide vaccine in adults

Conditions: Pneumococcal Infections

Summary: this study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vpnc) compared with 23-valent pneumococcal polysaccharide vaccine (23vps). although the study started with only 1 population, amendments to the original protocol will now reflect three participant populations. three age cohorts will be enrolled. the first cohort (age 60-64) will be blinded. cohort 2 (age 50-59) and cohort 3 (age 18-49) are open label. subjects in cohorts 1 and 2 will receive 2 vaccinations 3-4 years apart. subjects in cohort 3 will receive 1 vaccination. all participants should be naïve of 23vps. comparisons of immune responses from the different cohorts will be done.


Eligibility criteria:
inclusion criteria: * first cohort: healthy male and female adults 60 to 64 years of age at time of enrollment. * second cohort: healthy male and female adults 50 to 59 years of age at time of enrollment. * third cohort: healthy male and female adults 18 to 49 years of age at time of enrollment. exclusion criteria: * previous immunization with any licensed or experimental pneumococcal vaccine. * serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (copd) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study. * known or suspected impairment of immunological function.

Keywords: vaccine pneumococcal infections prevention and control
time lapse assisted embryo selection versus non invasive pgt-a assisted embryo selection

Conditions: Infertility; Aneuploidy; Chromosome Abnormality

Summary: this is a prospective randomised study of the evaluation of the clinical ivf results after time lapse assisted embryo selection versus non-invasive pgt-a assisted embryo selection in subfertile women.

a randomized prospective study focusing on subfertile women undergoing ivf treatment followed by embryo transfer on the blastocyst stage. women assigned to group a proceed to embryo transfer, after time lapse assisted embryo selection, while women of group b after non-invasive pgt-a assisted embryo selection. ivf outcomes, regarding the success rate of the trasnfer and the time required to achieve conception is studied in both groups.

Eligibility criteria:
inclusion criteria: * women who followed ivf treatment * 39 years old or younger * single embryo transfer * blastocyst stage cultured embryos exclusion criteria: * women over the age of 39 years * not blastocyst transfer (transfers performed at earlier embryo stage) * double embryotransfer * women who had invasive pgt-a test * women whose embryos were not time-lapse monitored

Keywords: ivf pgt-a non- invasive pgt-a time lapse embryo selection
toremifene in treating patients with desmoid tumors

Conditions: Desmoid Tumor

Summary: rationale: estrogen can stimulate the growth of cancer cells. hormone therapy using toremifene may fight the growth of desmoid tumors by reducing the production of estrogen. purpose: phase ii trial to study the effectiveness of toremifene in treating patients with desmoid tumors.

objectives: i. determine the efficacy of toremifene in terms of tumor response rate and symptom relief in patients with desmoid tumors. ii. determine the safety of this regimen in these patients. iii. determine the quality of life of patients treated with this regimen. outline: patients are stratified by gender. patients receive oral toremifene daily until complete or maximal response in the absence of disease progression or unacceptable toxicity. patients achieving maximal response undergo complete resection of all lesions, if feasible. nonsurgical candidates with severe or life-threatening disease not achieving partial or complete response or symptom relief at 12 months may continue on toremifene at the discretion of the study chairperson. patients with stable disease who do not undergo surgery may continue on toremifene for a maximum of 12 months at the discretion of the treating physician. patients who continue to experience symptom relief at 12 months may continue on toremifene at the discretion of the study chairperson. quality of life is assessed at baseline and at 2 and 6 months. patients are followed every 8 weeks for 4 years and then annually thereafter. projected accrual: a total of 24-72 (12-36 per stratum) will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven primary or recurrent desmoid tumor unresectable and symptomatic or progressive disease or disease for which a mutilating surgery would be required for complete resection bidimensionally measurable or clinically evaluable disease patient characteristics: age: 16 and over (no prepubertal patients) performance status: 0-2 life expectancy: more than 2 months hematopoietic: absolute granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 2 mg/dl transaminases no greater than 3 times upper limit of normal (uln) alkaline phosphatase no greater than 3 times uln renal: not specified cardiovascular: no history of deep vein thrombosis other: not pregnant fertile patients must use effective barrier contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: no concurrent dexamethasone for antiemesis no other concurrent hormonal therapy, including hormonal contraceptives radiotherapy: not specified surgery: see disease characteristics

Keywords: desmoid tumor